Nothing Special   »   [go: up one dir, main page]

You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (17)

Search Parameters:
Keywords = aortic valve calcification score

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 898 KiB  
Article
Interrater Variability of ML-Based CT-FFR in Patients without Obstructive CAD before TAVR: Influence of Image Quality, Coronary Artery Calcifications, and Location of Measurement
by Robin F. Gohmann, Adrian Schug, Christian Krieghoff, Patrick Seitz, Nicolas Majunke, Maria Buske, Fyn Kaiser, Sebastian Schaudt, Katharina Renatus, Steffen Desch, Sergey Leontyev, Thilo Noack, Philipp Kiefer, Konrad Pawelka, Christian Lücke, Ahmed Abdelhafez, Sebastian Ebel, Michael A. Borger, Holger Thiele, Christoph Panknin, Mohamed Abdel-Wahab, Matthias Horn and Matthias Gutberletadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(17), 5247; https://doi.org/10.3390/jcm13175247 - 4 Sep 2024
Viewed by 1140
Abstract
Objectives: CT-derived fractional flow reserve (CT-FFR) can improve the specificity of coronary CT-angiography (cCTA) for ruling out relevant coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR). However, little is known about the reproducibility of CT-FFR and the influence of [...] Read more.
Objectives: CT-derived fractional flow reserve (CT-FFR) can improve the specificity of coronary CT-angiography (cCTA) for ruling out relevant coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR). However, little is known about the reproducibility of CT-FFR and the influence of diffuse coronary artery calcifications or segment location. The objective was to assess the reliability of machine-learning (ML)-based CT-FFR prior to TAVR in patients without obstructive CAD and to assess the influence of image quality, coronary artery calcium score (CAC), and the location of measurement within the coronary tree. Methods: Patients assessed for TAVR, without obstructive CAD on cCTA were evaluated with ML-based CT-FFR by two observers with differing experience. Differences in absolute values and categorization into hemodynamically relevant CAD (CT-FFR ≤ 0.80) were compared. Results in regard to CAD were also compared against invasive coronary angiography. The influence of segment location, image quality, and CAC was evaluated. Results: Of the screened patients, 109/388 patients did not have obstructive CAD on cCTA and were included. The median (interquartile range) difference of CT-FFR values was −0.005 (−0.09 to 0.04) (p = 0.47). Differences were smaller with high values. Recategorizations were more frequent in distal segments. Diagnostic accuracy of CT-FFR between both observers was comparable (proximal: Δ0.2%; distal: Δ0.5%) but was lower in distal segments (proximal: 98.9%/99.1%; distal: 81.1%/81.6%). Image quality and CAC had no clinically relevant influence on CT-FFR. Conclusions: ML-based CT-FFR evaluation of proximal segments was more reliable. Distal segments with CT-FFR values close to the given threshold were prone to recategorization, even if absolute differences between observers were minimal and independent of image quality or CAC. Full article
(This article belongs to the Topic AI in Medical Imaging and Image Processing)
Show Figures

Figure 1

Figure 1
<p>Diagram of the 18-segment model of the coronary tree. Diagram showing the coronary tree with its division into 18 segments according to the SCCT guidelines [<a href="#B16-jcm-13-05247" class="html-bibr">16</a>]. Shaded segments were defined as proximal in this study. L = left; LAD = left anterior descending artery; PDA = posterior descending artery; PLB = posterior-lateral branch; R = right; RCA = right coronary artery; SCCT = Society of Cardiovascular Computed Tomography.</p>
Full article ">Figure 2
<p>CT-FFR values at patient level. Bland-Altman plot showing the distribution of differences in CT-FFR values between both observers. Differences between both observers are overall very small. The plot shows no indication of a systematic bias. Lower mean CT-FFR values show one outlier (CT-FFR difference of −0.45 at a CT-FFR mean value of 0.58), which has been omitted from the plot for clarity. Lower mean CT-FFR values also show a larger heterogeneity of CT-FFR differences. CT-FFR = CT-derived fractional flow reserve. Dashed horizontal lines represent the mean difference (middle line) and the upper and lower limits of agreement (±1.96 SD, upper and lower lines).</p>
Full article ">
12 pages, 1277 KiB  
Article
Treating Aortic Valve Stenosis for Vitality Improvement: The TAVI Study
by Donato Tartaglione, Dario Prozzo, Renatomaria Bianchi, Giovanni Ciccarelli, Maurizio Cappelli Bigazzi, Francesco Natale, Paolo Golino and Giovanni Cimmino
Diseases 2024, 12(8), 175; https://doi.org/10.3390/diseases12080175 - 2 Aug 2024
Viewed by 1352
Abstract
Background: Degenerative aortic valve stenosis (AS) is the most common valvular heart disease among the elderly. Once cardiac symptoms occur, current guidelines recommend aortic valve replacement. Progressive degeneration/calcification reduces leaflet mobility with gradual cardiac output (CO) impairment. Low CO might induce abnormal brain-aging [...] Read more.
Background: Degenerative aortic valve stenosis (AS) is the most common valvular heart disease among the elderly. Once cardiac symptoms occur, current guidelines recommend aortic valve replacement. Progressive degeneration/calcification reduces leaflet mobility with gradual cardiac output (CO) impairment. Low CO might induce abnormal brain-aging with cognitive impairment and increased risk of dementia, such as Alzheimer’s disease or vascular dementia. On the contrary, cognitive improvement has been reported in patients in whom CO was restored. Transcatheter aortic valve implantation (TAVI) has proven to be a safe alternative to conventional surgery, with a similar mid-term survival and stroke risk even in low-risk patients. TAVI is associated with an immediate CO improvement, also effecting the cerebrovascular system, leading to an increased cerebral blood flow. The correlation between TAVI and cognitive improvement is still debated. The present study aims at evaluating this relationship in a cohort of AS patients where cognitive assessment before and after TAVI was available. Methods: a total of 47 patients were retrospectively selected. A transcranial Doppler ultrasound (TCD) before and after TAVI, a quality of life (QoL) score, as well as a mini-mental state examination (MMSE) at baseline and up to 36 months, were available. Results: TAVI was associated with immediate increase in mean cerebral flow at TCD. MMSE slowly increase at 36-months follow-up with improved QoL mainly for symptoms, emotions and social interactions. Conclusions: this proof-of-concept study indicates that TAVI might induce cognitive improvement in the long-term as a result of multiple factors, such as cerebral flow restoration and a better QoL. Full article
Show Figures

Figure 1

Figure 1
<p>Transcranial Doppler evaluation: (<b>A</b>) The transtemporal window with Willis circle visualize at color Doppler. A representative measurement of PSV and EDV is reported in (<b>B</b>) (pre-TAVI) and (<b>C</b>) (post-TAVI). The average PSV value pre-procedure was 50.21 ± 18.5 cm/s. This value increased significantly (<span class="html-italic">p</span> &lt; 0.0001) in the post-procedure measurements, reaching a mean value of 62.9 ± 19 cm/s (<b>D</b>). Significant variations occurred in the measurement of End Diastolic Velocity (EDV), which changed from a mean of 20.05 ± 11.1 cm/s to 24.4 ± 16.1 cm/s post-procedure (<span class="html-italic">p</span> &lt; 0.005; (<b>E</b>)). The resulted mean cerebral flow (MCF) was also significantly improved from 30.11 ± 13.2 cm/s to 37.2 ± 15.9 cm/s (<b>F</b>). * = <span class="html-italic">p</span> &lt; 0.01; one-way ANOVA with Tukey’s post hoc test.</p>
Full article ">Figure 2
<p>TASQ score graphical representation before and after TAVI: a significant improvement was observed started from 3 months after the procedure for physical symptoms (7 ± 1.7 vs. 7.8 ± 2.1, <span class="html-italic">p</span> = 0.04) and from 6 months for physical limitations (14.7 ± 2.9 vs. 16.4 ± 5, <span class="html-italic">p</span> = 0.04). These improvements involved physical symptoms, physical limitations and social limitations from 12 months up to 36 months. The overall summary significantly improves at the evaluation performed at 24 months (54.7 ± 12.6 vs. 63.4 ± 25.9, <span class="html-italic">p</span> = 0.04), remaining fairly steady at 36 months. TASQ physical limitations and emotional aspects greatly improved over time. Health expectation was almost unmodified up to one year after TAVI (3.9 ± 1.9 vs. 4.4 ± 1.8, <span class="html-italic">p</span> = 0.19). Starting from two-years follow-up, a significant improvement was observed (2.9 ± 2.1 vs. 4.4 ± 1.8, <span class="html-italic">p</span> &lt; 0.01) up to 36 months. (# = <span class="html-italic">p</span> &lt; 0.05, * = <span class="html-italic">p</span> &lt; 0.01; one-way ANOVA with Tukey’s post hoc test).</p>
Full article ">Figure 3
<p>MMSE evaluation: The mean MMSE score before TAVI was 25.15 ± 1.89. No significant changes were observed at 3 (25.22 ± 1.85, <span class="html-italic">p</span> = 0.8 vs. baseline) 6 (25.24 ± 1.84, <span class="html-italic">p</span> = 0.8 vs. baseline) and 12 months (25.4 ± 1.77, <span class="html-italic">p</span> = 0.5 vs. baseline) after the procedure. The MMSE score post TAVI improved significantly by two-years follow-up to a mean of 26.13 ± 1.28, <span class="html-italic">p</span> = 0.0047, vs. pre-TAVI, mean Δ 0.98. After this initial rise, the post-TAVI MMSE score remained fairly steady, at around an average of 26.28 ± 1.17, <span class="html-italic">p</span> = 0.001, vs. pre-TAVI, mean Δ 1.13 up to three years post-procedure (* = <span class="html-italic">p</span> &lt; 0.01; one-way ANOVA with Tukey’s post hoc test).</p>
Full article ">
33 pages, 2185 KiB  
Review
Aortic Valve Calcium Score: Applications in Clinical Practice and Scientific Research—A Narrative Review
by Paweł Gać, Arkadiusz Jaworski, Filip Grajnert, Katarzyna Kicman, Agnieszka Trejtowicz-Sutor, Konrad Witkowski, Małgorzata Poręba and Rafał Poręba
J. Clin. Med. 2024, 13(14), 4064; https://doi.org/10.3390/jcm13144064 - 11 Jul 2024
Viewed by 1984
Abstract
In this narrative review, we investigate the essential role played by the computed tomography Aortic Valve Calcium Score (AVCS) in the cardiovascular diagnostic landscape, with a special focus on its implications for clinical practice and scientific research. Calcific aortic valve stenosis is the [...] Read more.
In this narrative review, we investigate the essential role played by the computed tomography Aortic Valve Calcium Score (AVCS) in the cardiovascular diagnostic landscape, with a special focus on its implications for clinical practice and scientific research. Calcific aortic valve stenosis is the most prevalent type of aortic stenosis (AS) in industrialized countries, and due to the aging population, its prevalence is increasing. While transthoracic echocardiography (TTE) remains the gold standard, AVCS stands out as an essential complementary tool in evaluating patients with AS. The advantage of AVCS is its independence from flow; this allows for a more precise evaluation of patients with discordant findings in TTE. Further clinical applications of AVCS include in the assessment of patients before transcatheter aortic valve replacement (TAVR), as it helps in predicting outcomes and provides prognostic information post-TAVR. Additionally, we describe different AVCS thresholds regarding gender and the anatomical variations of the aortic valve. Finally, we discuss various scientific studies where AVCS was applied. As AVCS has some limitations, due to the pathophysiologies of AS extending beyond calcification and gender differences, scientists strive to validate contrast-enhanced AVCS. Furthermore, research on developing radiation-free methods of measuring calcium content is ongoing. Full article
Show Figures

Figure 1

Figure 1
<p>Examples of cardiac computed tomography images in the AVCS assessment protocol: (<b>A</b>) 67-year-old woman with AVCS 1578; (<b>B</b>) 74-year-old man with AVCS 5323 (images from P.G.’s clinical practice). Purple—calcifications in the aortic valve, yellow—calcifications in the LAD branch, blue—calcifications in the LCx branch, pink—calcifications in other anatomical structures, red—calcifications in the RCA.</p>
Full article ">Figure 2
<p>Sample images of the aortic valve in cardiac computed tomography: (<b>A</b>) bicuspid aortic valve; (<b>B</b>) tricuspid aortic valve (images from P.G.’s clinical practice).</p>
Full article ">Figure 3
<p>AVA measurement in an example computed tomography cardiac image (from P.G.’s clinical practice). In the application from which the image originates, [1] signifies a measurement made, which is described in the following text.</p>
Full article ">Figure 4
<p>Elementary measurements in cardiac computed tomography before TAVR: (<b>A</b>) Dimensions, circumference, and surface area of the aortic annulus. (<b>B</b>) Dimensions, circumference, and surface area of the aortic bulb. (<b>C</b>) Distance of the RCA origin from the aortic annulus. (<b>D</b>) Distance of the LM origin from the aortic annulus. (<b>E</b>) Aortic bulb height (images from P.G.’s clinical practice).</p>
Full article ">
10 pages, 4475 KiB  
Article
Quantification of Aortic Valve Calcification in Contrast-Enhanced Computed Tomography
by Danai Laohachewin, Philipp Ruile, Philipp Breitbart, Jan Minners, Nikolaus Jander, Martin Soschynski, Christopher L. Schlett, Franz-Josef Neumann, Dirk Westermann and Manuel Hein
J. Clin. Med. 2024, 13(8), 2386; https://doi.org/10.3390/jcm13082386 - 19 Apr 2024
Viewed by 1324
Abstract
Background: The goal of our study is to evaluate a method to quantify aortic valve calcification (AVC) in contrast-enhanced computed tomography for patients with suspected severe aortic stenosis pre-interventionally. Methods: A total of sixty-five patients with aortic stenosis underwent both a [...] Read more.
Background: The goal of our study is to evaluate a method to quantify aortic valve calcification (AVC) in contrast-enhanced computed tomography for patients with suspected severe aortic stenosis pre-interventionally. Methods: A total of sixty-five patients with aortic stenosis underwent both a native and a contrast-enhanced computed tomography (CECT) scan of the aortic valve (45 in the training cohort and 20 in the validation cohort) using a standardized protocol. Aortic valve calcification was semi-automatically quantified via the Agatston score method for the native scans and was used as a reference. For contrast-enhanced computed tomography, a calcium threshold of the Hounsfield units of the aorta plus four times the standard deviation was used. Results: For the quantification of aortic valve calcification in contrast-enhanced computed tomography, a conversion formula (691 + 1.83 x AVCCECT) was derived via a linear regression model in the training cohort. The validation in the second cohort showed high agreement for this conversion formula with no significant proportional bias (Bland–Altman, p = 0.055) and with an intraclass correlation coefficient in the validation cohort of 0.915 (confidence interval 95% 0.786–0.966) p < 0.001. Conclusions: Calcium scoring in patients with aortic valve stenosis can be performed using contrast-enhanced computed tomography with high validity. Using a conversion factor led to an excellent agreement, thereby obviating an additional native computed tomography scan. This might contribute to a decrease in radiation exposure. Full article
Show Figures

Figure 1

Figure 1
<p>Sample images of native computed tomography showing aortic calcification with the semi-automatic detection of aortic valve calcification with an attenuation threshold of ≥130 Hounsfield units. (<b>A</b>): A two-dimensional representation of the aortic valve in non-contrast computed tomography. (<b>B</b>): A semi-automatic quantification for the Agatston calculation; green = the semi-automatic selection of the aortic valve; pink = detections of calcification at a predetermined threshold of ≥130 Hounsfield units; red arrow = aortic valve; black arrow = calcified structures such as coronary arteries.</p>
Full article ">Figure 2
<p>Sample images of a contrast-enhanced computed tomography showing aortic calcification. (<b>A</b>) The dynamic threshold is determined by measuring the attenuation of the ascending aorta adding four times the standard deviation. (<b>B</b>) A visualization of calcification using the new threshold. (<b>C</b>) This new threshold is then used for the semi-automatic detection of aortic calcification. Red-bordered structures = semi-automatic quantifications of a calcified aortic valve.</p>
Full article ">Figure 3
<p>The correlation of aortic valve calcification quantification on contrast-enhanced computed tomography and the standard Agatston score on non-contrast-enhanced computed tomography with the line of best fit.</p>
Full article ">Figure 4
<p>The Bland–Altman plot comparing the standard Agatston score versus the calculated contrast-enhanced imaging-derived Agatston score for aortic valve calcium quantification (<span class="html-italic">p</span> = 0.055).</p>
Full article ">
16 pages, 2232 KiB  
Article
Albumin Redox Modifications Promote Cell Calcification Reflecting the Impact of Oxidative Status on Aortic Valve Disease and Atherosclerosis
by Tamara Sastre-Oliva, Nerea Corbacho-Alonso, Elena Rodriguez-Sanchez, Elisa Mercado-García, Ines Perales-Sanchez, German Hernandez-Fernandez, Cristina Juarez-Alia, Teresa Tejerina, Luis F. López-Almodóvar, Luis R. Padial, Pedro L. Sánchez, Ernesto Martín-Núñez, Natalia López-Andrés, Gema Ruiz-Hurtado, Laura Mourino-Alvarez and Maria G. Barderas
Antioxidants 2024, 13(1), 108; https://doi.org/10.3390/antiox13010108 - 16 Jan 2024
Cited by 2 | Viewed by 2028
Abstract
Calcific aortic valve disease (CAVD) and coronary artery disease (CAD) are related cardiovascular diseases in which common mechanisms lead to tissue calcification. Oxidative stress plays a key role in these diseases and there is also evidence that the redox state of serum albumin [...] Read more.
Calcific aortic valve disease (CAVD) and coronary artery disease (CAD) are related cardiovascular diseases in which common mechanisms lead to tissue calcification. Oxidative stress plays a key role in these diseases and there is also evidence that the redox state of serum albumin exerts a significant influence on these conditions. To further explore this issue, we used multimarker scores (OxyScore and AntioxyScore) to assess the global oxidative status in patients with CAVD, with and without CAD, also evaluating their plasma thiol levels. In addition, valvular interstitial cells were treated with reduced, oxidized, and native albumin to study how this protein and its modifications affect cell calcification. The differences we found suggest that oxidative status is distinct in CAVD and CAD, with differences in redox markers and thiol levels. Importantly, the in vitro interstitial cell model revealed that modified albumin affects cell calcification, accelerating this process. Hence, we show here the importance of the redox system in the development of CAVD, emphasizing the relevance of multimarker scores, while also offering evidence of how the redox state of albumin influences vascular calcification. These data highlight the relevance of understanding the overall redox processes involved in these diseases, opening the door to new studies on antioxidants as potential therapies for these patients. Full article
Show Figures

Figure 1

Figure 1
<p>Workflow of the study. (<b>A</b>) Different markers of oxidative damage and antioxidant defense, including thiol levels, were measured in plasma samples from patients with CAVD, with and without CAD. (<b>B</b>) Human VICs were treated with oxidized, reduced, and native HSA. Subsequently, calcification of these cells was assessed by using Alizarin Red staining. Microscope images size is 665.6 µm × 665.6 µm.</p>
Full article ">Figure 2
<p>Markers of oxidative status in plasma from the four groups of study. (<b>A</b>) Markers of oxidative damage, including protein carbonyls, 8-hydroxy-2′-deoxyguanosine (8-OHdG) xanthine oxidase (XOD) activity and oxidized LDL (oxLDL) (n = 15 subjects/each group). (<b>B</b>) Markers of antioxidants defense, including total antioxidant capacity (TAC), superoxide dismutase (SOD) activity and catalase (CAT) activity (n = 15 subjects/each group). (<b>C</b>) Free reduced thiols (n = 14 subjects/CAD group and n = 17 subjects/C, CAVD and CAVD + CAD group). Data are represented as the mean ± SD. AUC, Area under the curve; C, Controls; CAD, Coronary artery disease; CAVD, Calcific aortic valve disease. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 3
<p>Multimarker scores of (<b>A</b>) oxidative damage (OxyScore) and (<b>B</b>) antioxidant defense (AntiOxyscore) (n = 15 subjects/each group). C, Controls; CAD, Coronary artery disease; CAVD, Calcific aortic valve disease. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 4
<p>Results from in vitro model. (<b>A</b>) Immunoblot of modified HSA. Reduced HSA (RedHSA) was labeled with SulfoBiotics-PEG-PCMal, which produces a mobility shift corresponding to approximately 5 kDa for each molecule of PEG-PCMal bound to a free thiol group of the target protein. Thus, after the blotting, several bands corresponding to RedHSA are observed (from 60 to 150 kDa), while the lane of native HSA only shows one band. Oxidized HSA (OxHSA) was evaluated using OxyBlot Protein Oxidation Detection Kit. This kit allows the immunodetection of carbonyl groups through DNP-derivatization and subsequent detection of this DNP moiety with a specific primary antibody. It can be observed that the bands corresponding to OxHSA are more intense than the bands corresponding to native HSA. (<b>B</b>) Representative images of the Alizarin Red staining at a concentration of 1 mg/mL of modified or native HSA after 24 h of treatment. Microscope images size is 665.6 µm × 665.6 µm. (<b>C</b>) Calcification levels of cells cultured for 24 h in medium for fibroblast (FIBm) when supplemented with different concentrations of modified or native HSA. (<b>D</b>) Calcification levels of cells cultured for 24 h in osteogenic medium (OSTm) when supplemented with different concentrations of modified or native HAS was measured using Alizarin red staining. All experiments were performed in triplicate. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 5
<p>Hypothesis about the effect of oxidized HSA (OxHSA) in medium for fibroblasts (FIBm) and reduced HSA (RedHSA) in osteogenic medium (OSTm). In both cases, an intense calcification is observed in valvular interstitial cells, but OxHSA is believed to induce proinflammatory cytokines and reactive oxygen species, while RedHSA may act as a carrier of the osteogenic components that have the OSTm.</p>
Full article ">
12 pages, 338 KiB  
Article
Cardiovascular Calcifications Are Correlated with Inflammation in Hemodialysis Patients
by Dorin Dragoș, Delia Timofte, Mihai-Teodor Georgescu, Maria-Mirabela Manea, Ileana Adela Vacaroiu, Dorin Ionescu and Andra-Elena Balcangiu-Stroescu
Medicina 2023, 59(10), 1801; https://doi.org/10.3390/medicina59101801 - 10 Oct 2023
Cited by 1 | Viewed by 2176
Abstract
Background and Objectives: The main cause of morbidity and mortality in hemodialysis patients is cardiovascular disease, which is quite common. The main objective of our study was to investigate the relationship between oxidative stress, inflammation, and vascular and valvular calcifications in hemodialysis [...] Read more.
Background and Objectives: The main cause of morbidity and mortality in hemodialysis patients is cardiovascular disease, which is quite common. The main objective of our study was to investigate the relationship between oxidative stress, inflammation, and vascular and valvular calcifications in hemodialysis patients. Materials and Methods: This observational study had 54 hemodialysis patients, with an average age of 60.46 ± 13.18 years. Cardiovascular ultrasound was used to detect and/or measure aortic and mitral valve calcifications, carotid and femoral atheroma plaques, and common carotid intima-media thickness. The aortic calcification score was determined using a lateral abdomen plain radiograph. The inflammatory, oxidative, metabolic, and dietary statuses, as well as demographic characteristics, were identified. Results: There were significant correlations between the levels of IL-6 and carotid plaque number (p = 0.003), fibrinogen level and aortic valve calcifications (p = 0.05), intima-media thickness (p = 0.0007), carotid plaque number (p = 0.035), femoral plaque number (p = 0.00014), and aortic calcifications score (p = 0.0079). Aortic annulus calcifications (p = 0.03) and intima-media thickness (p = 0.038) were adversely linked with TNF-α. Nutrition parameters were negatively correlated with atherosclerosis markers: number of carotid plaques with albumin (p = 0.013), body mass index (p = 0.039), and triglycerides (p = 0.021); number of femoral plaques with phosphorus (0.013), aortic calcifications score with albumin (p = 0.051), intima-media thickness with LDL-cholesterol (p = 0.042). Age and the quantity of carotid plaques, femoral plaques, and aortic calcifications were linked with each other (p = 0.0022, 0.00011, and 0.036, respectively). Aortic annulus calcifications (p = 0.011), aortic valve calcifications (p = 0.023), and mitral valve calcifications (p = 0.018) were all associated with an increased risk of death. Conclusions: Imaging measures of atherosclerosis are adversely connected with dietary status and positively correlated with markers of inflammation and risk of mortality. Full article
(This article belongs to the Special Issue Cardiovascular Disease and Hemodialysis)
14 pages, 2008 KiB  
Article
Predictors of Conduction Disturbances Requiring New Permanent Pacemaker Implantation following Transcatheter Aortic Valve Implantation Using the Evolut Series
by Mahmoud Abdelshafy, Ahmed Elkoumy, Hesham Elzomor, Mohammad Abdelghani, Ruth Campbell, Ciara Kennedy, William Kenny Gibson, Simone Fezzi, Philip Nolan, Max Wagener, Shahram Arsang-Jang, Sameh K. Mohamed, Mansour Mostafa, Islam Shawky, Briain MacNeill, Angela McInerney, Darren Mylotte and Osama Soliman
J. Clin. Med. 2023, 12(14), 4835; https://doi.org/10.3390/jcm12144835 - 22 Jul 2023
Cited by 3 | Viewed by 1719
Abstract
(1) Background: Conduction disturbance requiring a new permanent pacemaker (PPM) after transcatheter aortic valve implantation (TAVI) has traditionally been a common complication. New implantation techniques with self-expanding platforms have reportedly reduced the incidence of PPM. We sought to investigate the predictors of PPM [...] Read more.
(1) Background: Conduction disturbance requiring a new permanent pacemaker (PPM) after transcatheter aortic valve implantation (TAVI) has traditionally been a common complication. New implantation techniques with self-expanding platforms have reportedly reduced the incidence of PPM. We sought to investigate the predictors of PPM at 30 days after TAVI using Evolut R/PRO/PRO+; (2) Methods: Consecutive patients who underwent TAVI with the Evolut platform between October 2019 and August 2022 at University Hospital Galway, Ireland, were included. Patients who had a prior PPM (n = 10), valve-in-valve procedures (n = 8) or received >1 valve during the index procedure (n = 3) were excluded. Baseline clinical, electrocardiographic (ECG), echocardiographic and multislice computed tomography (MSCT) parameters were analyzed. Pre-TAVI MSCT analysis included membranous septum (MS) length, a semi-quantitative calcification analysis of the aortic valve leaflets, left ventricular outflow tract, and mitral annulus. Furthermore, the implantation depth (ID) was measured from the final aortography. Multivariate binary logistic analysis and receiver operating characteristic (ROC) curve analysis were used to identify independent predictors and the optimal MS and ID cutoff values to predict new PPM requirements, respectively; (3) Results: A total of 129 TAVI patients were included (age = 81.3 ± 5.3 years; 36% female; median EuroSCORE II 3.2 [2.0, 5.4]). Fifteen patients (11.6%) required PPM after 30 days. The patients requiring new PPM at 30 days were more likely to have a lower European System for Cardiac Operative Risk Evaluation II, increased prevalence of right bundle branch block (RBBB) at baseline ECG, have a higher mitral annular calcification severity and have a shorter MS on preprocedural MSCT analysis, and have a ID, as shown on the final aortogram. From the multivariate analysis, pre-TAVI RBBB, MS length, and ID were shown to be predictors of new PPM. An MS length of <2.85 mm (AUC = 0.85, 95%CI: (0.77, 0.93)) and ID of >3.99 mm (area under the curve (AUC) = 0.79, (95% confidence interval (CI): (0.68, 0.90)) were found to be the optimal cut-offs for predicting new PPM requirements; (4) Conclusions: Membranous septum length and implantation depth were found to be independent predictors of new PPM post-TAVI with the Evolut platform. Patient-specific implantation depth could be used to mitigate the requirement for new PPM. Full article
(This article belongs to the Special Issue Valvular Heart Disease: From Basic to Clinical Advances)
Show Figures

Figure 1

Figure 1
<p>Study Flow chart.</p>
Full article ">Figure 2
<p>Time to new PPM implantation.</p>
Full article ">Figure 3
<p>ROC results of the predictability power of membranous septum length for prediction of PPM.</p>
Full article ">Figure 4
<p>ROC results of the predictability power of implantation depth for prediction of PPM.</p>
Full article ">Figure 5
<p>PR interval and QRS duration measurements pre-TAVI, post-TAVI and pre-discharge. The blue line represents the changes observed in each patient, while the red line depicts the average changes observed in all patients. Abbreviations: msec = millisecond; TAVI = transcatheter aortic valve implantation.</p>
Full article ">
8 pages, 1842 KiB  
Article
Assessment of Calcium Score Cutoff Point for Clinically Significant Aortic Stenosis on Lung Cancer Screening Program Low-Dose Computed Tomography—A Cross-Sectional Analysis
by Kaja Klein-Awerjanow, Witold Rzyman, Robert Dziedzic, Jadwiga Fijalkowska, Piotr Spychalski, Edyta Szurowska and Marcin Fijalkowski
Diagnostics 2023, 13(2), 246; https://doi.org/10.3390/diagnostics13020246 - 9 Jan 2023
Cited by 1 | Viewed by 2447
Abstract
Low-dose computed tomography (LDCT) is predominantly applied in lung cancer screening programs. Tobacco smoking is the main risk factor for developing lung cancer but is also common for cardiovascular diseases, including aortic stenosis (AS). Consequently, an increased prevalence of cardiovascular diseases is expected [...] Read more.
Low-dose computed tomography (LDCT) is predominantly applied in lung cancer screening programs. Tobacco smoking is the main risk factor for developing lung cancer but is also common for cardiovascular diseases, including aortic stenosis (AS). Consequently, an increased prevalence of cardiovascular diseases is expected in lung cancer screenees. Therefore, initial aortic valve calcification evaluation should be additionally performed on LDCT. The aim of this study was to estimate a calcium score (CS) cutoff point for clinically significant AS diagnosis based on LDCT, confirmed by echocardiographic examination. The study included 6631 heavy smokers who participated in a lung cancer screening program (MOLTEST BIS). LDCTs were performed on all individuals and were additionally assessed for aortic valve calcification with the use of CS according to the Agatston method. Patients with CS ≥ 900 were referred for echocardiography to confirm the diagnosis of AS and to evaluate its severity. Of 6631 individuals, 54 met the inclusion criteria and underwent echocardiography for confirmation and assessment of AS. Based on that data, receiver operating characteristic (ROC) curves of CS were plotted, and cutoff points for clinically significant AS diagnosis were established: A CS of 1758 for at least moderate AS had 85.71% (CI 65.36–95.02%) sensitivity and 75.76% (CI 58.98–87.17%) specificity; a CS of 2665 for severe AS had 87.5% (CI 73.89–94.54%) sensitivity and 76.92% (CI 49.74–91.82%) specificity. This is the first study to assess possible CS cutoff points for diagnosing clinically significant AS detected by LDCT in lung cancer screening participants. LDCT with CS assessment could enable early detection of patients with clinically significant AS and therefore identify patients who require appropriate treatment. Full article
(This article belongs to the Special Issue Cardiothoracic Imaging: Diagnostics and Modern Techniques)
Show Figures

Figure 1

Figure 1
<p>Algorithm of patient inclusion.</p>
Full article ">Figure 2
<p>Patient with massive calcification. The calcium score was 4075. In echocardiography, severe aortic stenosis was diagnosed.</p>
Full article ">Figure 3
<p>Calcium score stratified by AS category. Mean with 95% confidence intervals. Significant results of ANOVA test denoted.</p>
Full article ">Figure 4
<p>ROC for detection of at least moderate AS.</p>
Full article ">Figure 5
<p>ROC for detection of severe AS.</p>
Full article ">
11 pages, 647 KiB  
Article
Hemodynamic Performance of Two Current-Generation Transcatheter Heart Valve Prostheses in Severely Calcified Aortic Valve Stenosis
by Max Potratz, Kawa Mohemed, Hazem Omran, Lasha Gortamashvili, Kai Peter Friedrichs, Werner Scholtz, Smita Scholtz, Volker Rudolph, Cornelia Piper, Tomasz Gilis-Januszewski, René Schramm, Nobuyuki Furukawa, Jan Gummert, Sabine Bleiziffer and Tanja Katharina Rudolph
J. Clin. Med. 2022, 11(15), 4570; https://doi.org/10.3390/jcm11154570 - 5 Aug 2022
Cited by 5 | Viewed by 2001
Abstract
Background: Treatment of severely calcified aortic valve stenosis is associated with a higher rate of paravalvular leakage (PVL) and permanent pacemaker implantation (PPI). We hypothesized that the self-expanding transcatheter heart valve (THV) prostheses Evolut Pro (EPro) is comparable to the balloon-expandable Sapien 3 [...] Read more.
Background: Treatment of severely calcified aortic valve stenosis is associated with a higher rate of paravalvular leakage (PVL) and permanent pacemaker implantation (PPI). We hypothesized that the self-expanding transcatheter heart valve (THV) prostheses Evolut Pro (EPro) is comparable to the balloon-expandable Sapien 3 (S3) regarding hemodynamics, PPI, and clinical outcome in these patients. Methods: From 2014 to 2019, all patients with very severe calcification of the aortic valve who received an EPro or an S3 THV were included. Propensity score matching was utilized to create two groups of 170 patients. Results: At discharge, there was significant difference in transvalvular gradients (EPro vs. S3) (dPmean 8.1 vs. 11.1 mmHg, p ≤ 0.001) and indexed effective orifice area (EOAi) (1.1 vs. 0.9, p ≤ 0.001), as well as predicted EOAi (1 vs. 0.9, p ≤ 0.001). Moderate patient prosthesis mismatch (PPM) was significantly lower in the EPro group (17.7% vs. 38%, p ≤ 0.001), as well as severe PPM (2.9% vs. 8.8%, p = 0.03). PPI and the PVL rate as well as stroke, bleeding, vascular complication, and 30-day mortality were comparable. Conclusions: In patients with severely calcified aortic valves, both THVs performed similarly in terms of 30-day mortality, PPI rate, and PVL occurrence. However, patient prothesis mismatch was observed more often in the S3 group, which might be due to the intra-annular design. Full article
(This article belongs to the Special Issue Transcatheter Aortic Valve Replacement in 2021 and Beyond)
Show Figures

Figure 1

Figure 1
<p>(<bold>a</bold>) Paravalvular leakage ≥ the medium in relationship to the calcification burden in patients that received an EPro THV. The total calcification burden of these patients was sorted by size and then divided into thirds. (<bold>b</bold>) Paravalvular leakage ≥ the medium in relationship to the calcification burden in patients that received an S3 THV. The calcification burden was grouped similarly.</p>
Full article ">Figure A1
<p>This figure shows the unadjusted (before matching) and adjusted (after matching) standardized mean differences of the matched parameters. Absolute standardized mean differences &lt; 0.1 were considered indicator of adequate balance.</p>
Full article ">
13 pages, 1277 KiB  
Article
Cerebrovascular Events after Transcatheter Aortic Valve Replacement: The Difficulty in Predicting the Unpredictable
by Oliver Maier, Georg Bosbach, Kerstin Piayda, Shazia Afzal, Amin Polzin, Ralf Westenfeld, Christian Jung, Malte Kelm, Tobias Zeus and Verena Veulemans
J. Clin. Med. 2022, 11(13), 3902; https://doi.org/10.3390/jcm11133902 - 4 Jul 2022
Cited by 5 | Viewed by 1792
Abstract
Background: Cerebrovascular events (CVE) are feared complications following transcatheter aortic valve replacement (TAVR). We aimed to develop a new risk model for CVE prediction with the application of multimodal imaging. Methods: From May 2011 to August 2019, a total of 2015 patients underwent [...] Read more.
Background: Cerebrovascular events (CVE) are feared complications following transcatheter aortic valve replacement (TAVR). We aimed to develop a new risk model for CVE prediction with the application of multimodal imaging. Methods: From May 2011 to August 2019, a total of 2015 patients underwent TAVR at our institution. The study cohort was subdivided into a derivation cohort (n = 1365) and a validation cohort (n = 650) for risk model development. Results: Of 2015 patients, 72 (3.6%) developed TAVR-related CVE. Pre-procedural factors of our risk model were history of prior CVE, a larger aortic valve area (≥0.55 cm2), a large aortic angulation (≥48.5°), and enhanced calcification of the right coronary cusp (≥447.2 AU), left ventricular outflow tract (≥262.4 AU), and ascending thoracic aorta (≥116.4 AU). Our risk model was superior for in-hospital CVE prediction following TAVR in the establishment cohort (AUC 0.73, 95% CI 0.66–0.80; p < 0.001) compared to other risk scores, such as the EuroSCORE II or the CHA2DS2-VASc score. Conclusions: Although CVE prediction in patients undergoing TAVR is challenging due to the complex nature of the TAVR procedure, our study highlights that multimodal imaging is a promising approach to generate a more accurate risk model for CVE prediction. Full article
(This article belongs to the Special Issue New Updates Frontiers in Aortic Valve Disease)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Previously identified factors associated with cerebrovascular events after TAVR with three overlapping categories: patient-related factors, procedure-related factors, and post-procedural factors. AF = atrial fibrillation; AV = aortic valve; AVA = aortic valve area; BEV = balloon-expandable valve; TAVR = transcatheter aortic valve replacement; CVE = cerebrovascular event.</p>
Full article ">Figure 2
<p>Risk score models I and II in comparison with established risk scores in the derivation and validation cohorts. (<b>A</b>) ROC analysis for risk score model I in the derivation cohort. AUC = 0.73 (95% CI 0.66–0.80), <span class="html-italic">p</span> &lt; 0.001. Sensitivity = 70.6%; specificity = 69.0%; PPV = 19.5%; NPV = 95.7%. (<b>B</b>) ROC analysis for risk score model II in the derivation cohort. AUC = 0.79 (95% CI 0.73–0.86), <span class="html-italic">p</span> &lt; 0.001. Sensitivity = 74.5%; specificity = 68.2%; PPV = 19.9%; NPV = 96.2%. (<b>C</b>) Comparative model discrimination for risk score models I and II, and established risk scores for the derivation cohort. (<b>D</b>) ROC analysis for risk score model I in the validation cohort. AUC = 0.53 (95% CI 0.37–0.68), <span class="html-italic">p</span> = 0.77. Sensitivity = 25.0%; specificity = 63.3%; PPV = 6.4%; NPV = 89.4%. (<b>E</b>) ROC analysis for risk score model II in the validation cohort. AUC = 0.60 (95% CI 0.43–0.76), <span class="html-italic">p</span> = 0.08. Sensitivity = 66.7%; specificity = 58.3%; PPV = 13.8%; NPV = 94.6%. (<b>F</b>) Comparative model discrimination for risk score models I and II, and established risk scores for the validation cohort. AUC = area under the curve; NPV = negative predictive value; PPV = positive predictive value; ROC = receiver operating characteristic.</p>
Full article ">Figure 3
<p>Percentage of patients in the derivation cohort stratified by risk score models I and II. Percentage of patients in each group stratified by risk score model I (<b>A</b>) and model II (<b>B</b>). Groups are shown with <span class="html-italic">p</span>-values (* <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01).</p>
Full article ">
16 pages, 2930 KiB  
Article
Arterial Calcifications in Patients with Liver Cirrhosis Are Linked to Hepatic Deficiency of Pyrophosphate Production Restored by Liver Transplantation
by Audrey Laurain, Isabelle Rubera, Micheline Razzouk-Cadet, Stéphanie Bonnafous, Miguel Albuquerque, Valérie Paradis, Stéphanie Patouraux, Christophe Duranton, Olivier Lesaux, Georges Lefthériotis, Albert Tran, Rodolphe Anty, Philippe Gual, Antonio Iannelli and Guillaume Favre
Biomedicines 2022, 10(7), 1496; https://doi.org/10.3390/biomedicines10071496 - 24 Jun 2022
Cited by 5 | Viewed by 2432
Abstract
Liver fibrosis is associated with arterial calcification (AC). Since the liver is a source of inorganic pyrophosphate (PPi), an anti-calcifying compound, we investigated the relationship between plasma PPi ([PPi]pl), liver fibrosis, liver function, AC, and the hepatic expression of genes regulating PPi homeostasis. [...] Read more.
Liver fibrosis is associated with arterial calcification (AC). Since the liver is a source of inorganic pyrophosphate (PPi), an anti-calcifying compound, we investigated the relationship between plasma PPi ([PPi]pl), liver fibrosis, liver function, AC, and the hepatic expression of genes regulating PPi homeostasis. To that aim, we compared [PPi]pl before liver transplantation (LT) and 3 months after LT. We also assessed the expression of four key regulators of PPi in liver tissues and established correlations between AC, and scores of liver fibrosis and liver failure in these patients. LT candidates with various liver diseases were included. AC scores were assessed in coronary arteries, abdominal aorta, and aortic valves. Liver fibrosis was evaluated on liver biopsies and from non-invasive tests (FIB-4 and APRI scores). Liver functions were assessed by measuring serum albumin, ALBI, MELD, and Pugh–Child scores. An enzymatic assay was used to dose [PPi]pl. A group of patients without liver alterations from a previous cohort provided a control group. Gene expression assays were performed with mRNA extracted from liver biopsies and compared between LT recipients and the control individuals. [PPi]pl negatively correlated with APRI (r = −0.57, p = 0.001, n = 29) and FIB-4 (r = −0.47, p = 0.006, n = 29) but not with interstitial fibrosis index from liver biopsies (r = 0.07, p = 0.40, n = 16). Serum albumin positively correlated with [PPi]pl (r = 0.71; p < 0.0001, n = 20). ALBI, MELD, and Pugh–Child scores correlated negatively with [PPi]pl (r = −0.60, p = 0.0005; r = −0.56, p = 0.002; r = −0.41, p = 0.02, respectively, with n = 20). Liver fibrosis assessed on liver biopsies by FIB-4 and by APRI positively correlated with coronary AC (r = 0.51, p = 0.02, n = 16; r = 0.58, p = 0.009, n = 20; r = 0.41, p = 0.04, n = 20, respectively) and with abdominal aorta AC (r = 0.50, p = 0.02, n = 16; r = 0.67, p = 0.002, n = 20; r = 0.61, p = 0.04, n = 20, respectively). FIB-4 also positively correlated with aortic valve calcification (r = 0.40, p = 0.046, n = 20). The key regulator genes of PPi production in liver were lower in patients undergoing liver transplantation as compared to controls. Three months after surgery, serum albumin levels were restored to physiological levels (40 [37–44] vs. 35 [30–40], p = 0.009) and [PPi]pl was normalized (1.40 [1.07–1.86] vs. 0.68 [0.53–0.80] µmol/L, p = 0.0005, n = 12). Liver failure and/or fibrosis correlated with AC in several arterial beds and were associated with low plasma PPi and dysregulation of key proteins involved in PPi homeostasis. Liver transplantation normalized these parameters. Full article
Show Figures

Figure 1

Figure 1
<p>Flow chart and study plan. Legend: during the study period, 29 patients waiting for LT were included. At baseline, plasma PPi levels and liver fibrosis scores were determined in all patients; AC scores were determined in 20 LT candidates. Correlations between AC scores, fibrosis scores, and [PPi]pl were analyzed. Sixteen patients underwent LT. Biopsies from explanted liver prepared for interstitial fibrosis score were obtained from all patients, and 10 samples were prepared for mRNA extraction. Six patients without significant liver disease were used as controls for the gene expression assays. Twelve LT recipients reached the 3rd month post-surgery within the study period, and their [PPi]pl were compared with baseline values.</p>
Full article ">Figure 2
<p>Correlations between [PPi]pl and the non-invasive indexes of liver fibrosis before LT. Legend: APRI and FIB-4 scores were calculated with variables measured at baseline. The correlations were assessed with the Spearman’s test.</p>
Full article ">Figure 3
<p>Correlations between [PPi]pl and the indexes of liver failure before LT. Legend: MELD, ALBI, and Pugh–Child scores were calculated with variables measured at baseline. The correlations were assessed with the Spearman test.</p>
Full article ">Figure 4
<p>(<b>A</b>) mRNA levels of four genes regulating PPi homeostasis and of one gene related to fibrosis; (<b>B</b>) a schematic representation of PPi homeostasis in hepatocytes with respect to ectopic calcification. Legend 4(<b>A</b>): The figure shows the relative expression of genes directly involved in PPi homeostasis in the liver of LT candidates and controls. The gene expression values are normalized to RPLP0 mRNA levels. Results are expressed relative to the expression level in patients without fibrosis and statistically analyzed using the Mann–Whitney test. The results are shown as median ± interquartiles 25–75; Legend 4(<b>B</b>): The two diagrams are a representation of the relation between the PPi homeostasis in hepatocytes and arterial calcification. On the left panel (normal hepatocyte), PPi production and PPi hydrolysis are balanced, and the development of arterial calcifications is prevented. PPi production is initiated by the cellular release of ATP by ABCC6, which is then hydrolyzed by ENPP1 into PPi and AMP. PPi levels depend on NT5E, which generates adenosine from AMP. Adenosine normally inhibits the expression of ALPL, which encodes TNAP. In the right panel (hepatocyte in pathological liver), the decreased expression of ABCC6 and ENPP1 is consistent with the lower [PPi]pl we observed. Furthermore, sustain elevated plasma ALP activity enhances the PPi deficit and promotes arterial calcification.</p>
Full article ">Figure 5
<p>Correlations between arterial calcification scores and liver fibrosis indices in LTC. Legend: Liver fibrosis scores were calculated with variables measured at baseline (platelet count, AST, ALT) and the interstitial fibrosis index was measured on Masson trichrome-stained liver biopsies. The AC scores were measured on CT scans according to Agatston and log transformed. The length of the abdominal aorta was used to divide the abdominal aorta calcification score. The correlations were assessed with the Spearman test.</p>
Full article ">
11 pages, 2515 KiB  
Article
Head-to-Head Comparison of Different Software Solutions for AVC Quantification Using Contrast-Enhanced MDCT
by Ruben Evertz, Sebastian Hub, Sören J. Backhaus, Torben Lange, Karl Toischer, Johannes T. Kowallick, Gerd Hasenfuß and Andreas Schuster
J. Clin. Med. 2021, 10(17), 3970; https://doi.org/10.3390/jcm10173970 - 2 Sep 2021
Cited by 8 | Viewed by 2935
Abstract
Aortic valve calcification (AVC) in aortic stenosis patients has diagnostic and prognostic implications. Little is known about the interchangeability of AVC obtained from different multidetector computed tomography (MDCT) software solutions. Contrast-enhanced MDCT data sets of 50 randomly selected aortic stenosis patients were analysed [...] Read more.
Aortic valve calcification (AVC) in aortic stenosis patients has diagnostic and prognostic implications. Little is known about the interchangeability of AVC obtained from different multidetector computed tomography (MDCT) software solutions. Contrast-enhanced MDCT data sets of 50 randomly selected aortic stenosis patients were analysed using three different software vendors (3Mensio, CVI42, Syngo.Via). A subset of 10 patients were analysed twice for the estimation of intra-observer variability. Intra- and inter-observer variability were determined using the ICC reliability method, Bland-Altman analysis and coefficients of variation. No differences were revealed between the software solutions in the AVC calculations (3Mensio 941 ± 623, Syngo.Via 948 mm3 ± 655, CVI42 941 ± 637; p = 0.455). The best inter-vendor agreement was found between the CVI42 and the Syngo.Via (ICC 0.997 (CI 0.995–0.998)), followed by the 3Mensio and the CVI42 (ICC 0.996 (CI 0.922–0.998)), and the 3Mensio and the Syngo.Via (ICC 0.992 (CI 0.986–0.995)). There was excellent intra- (3Mensio: ICC 0.999 (0.995–1.000); CVI42: ICC 1.000 (0.999–1.000); Syngo.Via: ICC 0.998 (0.993–1.000)) and inter-observer variability (3Mensio: ICC 1.000 (0.999–1.000); CVI42: ICC 1.000 (1.000–1.000); Syngo.Via: ICC 0.996 (0.985–0.999)) for all software types. Contrast-enhanced MDCT-derived AVC scores are interchangeable between and reproducible within different commercially available software solutions. This is important since sufficient reproducibility, interchangeability and valid results represent prerequisites for accurate TAVR planning and its widespread clinical use. Full article
Show Figures

Figure 1

Figure 1
<p>Visualisation of Aortic Valve Calcification. A representative illustration of the region of interest (coronary view) and of the aortic valve (transversal view), using the different software types. Aortic valve calcification is marked and differently colour coded for the aortic cusps, respectively.</p>
Full article ">Figure 2
<p>AVC calculation using three software solutions. A comparison of AVC measured in a cohort of 50 patients, using three different software types. There was no significant difference in AVC (Friedmann test for continuous data with deviations from normality; <span class="html-italic">p</span> = 0.455). AVC: aortic valve calcification.</p>
Full article ">Figure 3
<p>AVC measurements for each patient, using three different software solutions. A representation of the individual measurements of AVC for each patient using the three different software types. AVC: aortic valve calcification.</p>
Full article ">Figure 4
<p>Bland-Altmann plots for inter-vendor agreement. The inter-vendor agreement on the degree of AVC. Bland-Altmann plots with limits of agreement (95% confidence intervals) demonstrate the inter-vendor reproducibility of MDCT-derived AVC. MDCT: multidetector computed tomography; AVC: aortic valve calcification.</p>
Full article ">Figure 5
<p>Bland-Altman plots for intra- and inter-observer agreement. The intra- and interobserver agreement on the degree of AVC. Bland-Altmann plots with limits of agreement (95% confidence intervals) demonstrate the reproducibility of MDCT-derived AVC using three different software solutions. The data for inter-observer reproducibility were derived by a second skilled observer. MDCT: multidetector computed tomography; AVC: aortic valve calcification.</p>
Full article ">Figure 6
<p>Intra-observer AVC measurements for the three different software solutions. An illustration of the AVC measured in the intra-observer setting. No significant differences were found. (<span class="html-italic">t</span>-Test for paired, normally distributed samples; 3 Meniso <span class="html-italic">p</span> = 0.209, CVI 42 <span class="html-italic">p</span> = 0.114, Syngo.Via <span class="html-italic">p</span> = 0.123). AVC: aortic valve calcification.</p>
Full article ">Figure 7
<p>Inter-observer AVC measurements for the three different software solutions. An illustration of the AVC measured in the inter-observer setting. No significant differences were found. (<span class="html-italic">t</span>-Test for paired, normally distributed samples; 3 Meniso <span class="html-italic">p</span> = 0.197, CVI 42 <span class="html-italic">p</span> = 0.653, Scheme 0). AVC: aortic valve calcification.</p>
Full article ">
16 pages, 815 KiB  
Article
Estimation of Aortic Valve Calcium Score Based on Angiographic Phase Versus Reduction of Ionizing Radiation Dose in Computed Tomography
by Paweł Gać, Bartłomiej Kędzierski, Piotr Macek, Krystyna Pawlas and Rafał Poręba
Life 2021, 11(7), 604; https://doi.org/10.3390/life11070604 - 23 Jun 2021
Cited by 2 | Viewed by 2147
Abstract
The aim of the study was to evaluate the estimation efficacy of aortic valve calcium score (AVCS) based on the multislice computed tomography (MSCT) angiographic phase. The evaluation of the reduced amount of ionizing radiation dose was performed because of this estimation. The [...] Read more.
The aim of the study was to evaluate the estimation efficacy of aortic valve calcium score (AVCS) based on the multislice computed tomography (MSCT) angiographic phase. The evaluation of the reduced amount of ionizing radiation dose was performed because of this estimation. The study included 51 consecutive patients who qualified for transcatheter aortic valve implantation (TAVI) (78.59 ± 5.72 years). All subjects underwent MSCT: in the native phase dedicated to AVCS as well as angiographic phases aimed to morphologically assess the aortic ostium and arterial accesses for TAVI. Based on the native phase, an AVCS assessment was performed for axial reconstructions at 3.0 mm and 2.0 mm slice thickness (AVCSnative3.0 and AVCSnative2.0). Based on the angiographic phase AVCS was estimated for axial reconstruction at 0.6 mm slice thickness with increased values of lesion density in aortic valve cusps/aortic valve annulus, which is considered a calcification, from a typical value of 130 HU to 500 HU and 600 HU (AVCSCTA0.6 500 HU and AVCSCTA0.6 600 HU). Mathematical formulations were developed, allowing for AVCS native calculation based on AVCS values estimated based on the angiographic phase: AVCSnative3.0 = 813.920 + 1.510 AVCSCTA0.6 500 HU; AVCSnative3.0 = 1235.863 + 1.817 AVCSCTA0.6 600 HU; AVCSnative2.0 = 797.471 + 1.393 AVCSCTA0.6 500 HU; AVCSnative2.0 = 1228.310 + 1.650 AVCSCTA0.6 600 HU. The amount of a potential reduction in dose length product (DLP) in the case of AVCS estimation was 4.45 ± 1.54%. In summary, relying solely on the angiographic phase of MSCT examination before TAVI, it is possible to conclusively estimate AVCS. This estimation results in a marked reduction in radiation dose in MSCT. Full article
Show Figures

Figure 1

Figure 1
<p>AVCS assessment in MSCT: (<b>A</b>) native phase, axial reconstruction, slice thickness: 3.0 mm, calcium detection threshold: density &gt;130 HU; (<b>B</b>) native phase, axial reconstruction, slice thickness: 2.0 mm, calcium detection threshold: density &gt;130 HU; (<b>C</b>) angiographic phase, axial reconstruction, slice thickness: 0.6 mm, calcium detection threshold: density &gt;500 HU; (<b>D</b>) angiographic phase, axial reconstruction, slice thickness: 0.6 mm, calcium detection threshold: density &gt;600 HU.</p>
Full article ">
14 pages, 1875 KiB  
Review
Cardiovascular Calcification as a Marker of Increased Cardiovascular Risk and a Surrogate for Subclinical Atherosclerosis: Role of Echocardiography
by Andrea Faggiano, Gloria Santangelo, Stefano Carugo, Gregg Pressman, Eugenio Picano and Pompilio Faggiano
J. Clin. Med. 2021, 10(8), 1668; https://doi.org/10.3390/jcm10081668 - 13 Apr 2021
Cited by 16 | Viewed by 4156
Abstract
The risk prediction of future cardiovascular events is mainly based on conventional risk factor assessment by validated algorithms, such as the Framingham Risk Score, the Pooled Cohort Equations and the European SCORE Risk Charts. The identification of subclinical atherosclerosis has emerged as a [...] Read more.
The risk prediction of future cardiovascular events is mainly based on conventional risk factor assessment by validated algorithms, such as the Framingham Risk Score, the Pooled Cohort Equations and the European SCORE Risk Charts. The identification of subclinical atherosclerosis has emerged as a promising tool to refine the individual cardiovascular risk identified by these models, to prognostic stratify asymptomatic individuals and to implement preventive strategies. Several imaging modalities have been proposed for the identification of subclinical organ damage, the main ones being coronary artery calcification scanning by cardiac computed tomography and the two-dimensional ultrasound evaluation of carotid arteries. In this context, echocardiography offers an assessment of cardiac calcifications at different sites, such as the mitral apparatus (including annulus, leaflets and papillary muscles), aortic valve and ascending aorta, findings that are associated with the clinical manifestation of atherosclerotic disease and are predictive of future cardiovascular events. The aim of this paper is to summarize the available evidence on clinical implications of cardiac calcification, review studies that propose semiquantitative ultrasound assessments of cardiac calcifications and evaluate the potential of ultrasound calcium scores for risk stratification and prevention of clinical events. Full article
(This article belongs to the Special Issue CT Coronary Angiography in Early Detection of Atherosclerosis)
Show Figures

Figure 1

Figure 1
<p>Transthoracic parasternal long-axis view showing aortic valve calcifications (arrows). RV = right ventricle, LV = left ventricle, LA = left atrium.</p>
Full article ">Figure 2
<p>Transthoracic parasternal short axis view showing a calcified mitral posterior annulus (arrow). RV = right ventricle.</p>
Full article ">Figure 3
<p>Transesophageal echocardiographic study of a protruding plaque in the descending aorta (arrow). Differences in the visual assessment of aortic atherosclerotic plaque between a 2D-based image (<b>A</b>) compared with the 3D-based image (<b>B</b>). The entire contour of the complex plaque is seen in the 3D image.</p>
Full article ">
15 pages, 2728 KiB  
Article
The Usefulness of [18F]F-Fluorodeoxyglucose and [18F]F-Sodium Fluoride Positron Emission Tomography Imaging in the Assessment of Early-Stage Aortic Valve Degeneration after Transcatheter Aortic Valve Implantation (TAVI)—Protocol Description and Preliminary Results
by Danuta Sorysz, Rafał Januszek, Anna Sowa-Staszczak, Anna Grochowska, Marta Opalińska, Maciej Bagieński, Barbara Zawiślak, Artur Dziewierz, Tomasz Tokarek, Agata Krawczyk-Ożóg, Stanisław Bartuś and Dariusz Dudek
J. Clin. Med. 2021, 10(3), 431; https://doi.org/10.3390/jcm10030431 - 22 Jan 2021
Cited by 4 | Viewed by 2880
Abstract
Transcatheter aortic valve implantation (TAVI) is now a well-established treatment for severe aortic stenosis. As the number of procedures and indications increase, the age of patients decreases. However, their durability and factors accelerating the process of degeneration are not well-known. The aim of [...] Read more.
Transcatheter aortic valve implantation (TAVI) is now a well-established treatment for severe aortic stenosis. As the number of procedures and indications increase, the age of patients decreases. However, their durability and factors accelerating the process of degeneration are not well-known. The aim of the study was to verify the possibility of using [18F]F-sodium fluoride ([18F]F-NaF) and [18F]F-fluorodeoxyglucose ([18F]F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing the intensity of TAVI valve degenerative processes. In 73 TAVI patients, transthoracic echocardiography (TTE) at initial (before TAVI), baseline (after TAVI), and during follow-up, as well as transesophageal echocardiography (TEE) and PET/CT, were performed using [18F]F-NaF and [18F]F-FDG at the six-month follow-up (FU) visit as a part of a two-year FU period. The morphology of TAVI valve leaflets were assessed in TEE, transvalvular gradients and effective orifice area (EOA) in TTE. Calcium scores and PET tracer activity were counted. We assessed the relationship between [18F]F-NaF and [18F]F-FDG PET/CT uptake at the 6 = month FU with selected indices e.g.,: transvalvular gradient, valve type, EOA and insufficiency grade at following time points after the TAVI procedure. We present the preliminary PET/CT ([18F]F-NaF, [18F]F-FDG) results at the six-month follow-up period as are part of an ongoing study, which will last two years FU. We enrolled 73 TAVI patients with the mean age of 82.49 ± 7.11 years. A significant decrease in transvalvular gradient and increase of effective orifice area and left ventricle ejection fraction were observed. At six months, FU valve thrombosis was diagnosed in four patients, while 7.6% of patients refused planned controls due to the COVID-19 pandemic. We noticed significant correlations between valve types, EOA and transaortic valve gradients, as well as [18F]F-NaF and [18F]F-FDG uptake in PET/CT. PET/CT imaging with the use of [18F]F-FDG and [18F]F-NaF is intended to be feasible, and it practically allows the standardized uptake value (SUV) to differentiate the area containing the TAVI leaflets from the SUV directly adjacent to the ring calcifications and the calcified native leaflets. This could become the seed for future detection and evaluation capabilities regarding the progression of even early degenerative lesions to the TAVI valve, expressed as local leaflet inflammation and microcalcifications. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

Figure 1
<p>TAVI valves included in the current study. (<b>A</b>) Acurate Neo (Boston Scientific SciMed Inc, Maple Grove, MN, USA); (<b>B</b>) Evolut PRO (Medtronic, Minneapolis, MN, USA); (<b>C</b>) Evolut R (Medtronic, Minneapolis, MN, USA); (<b>D</b>) Portico<sup>®</sup> valve (St. Jude Medical, St. Paul, MN, USA); (<b>E</b>) SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA); (<b>F</b>) SAPIEN 3 Ultra (Edwards Lifesciences, Irvine, CA, USA).</p>
Full article ">Figure 2
<p><b>Blue frame:</b> Transesophageal echocardiography (<b>A</b>) multi-D reconstruction: Acurate Neo valve with thrombotic leaflet (white arrows); (<b>B</b>) three dimensional reconstruction: Acurate Neo Valve with marked thrombotic leaflet (white arrow); <b>Yellow frame:</b> [<sup>18</sup>F]F-fluorodeoxyglucose positron emission tomography/computed tomography—no visible uptake at the level of the leaflets; (<b>C</b>) TAVI valve long axis, (<b>D</b>) TAVI valve short axis; <b>Green frame:</b> [<sup>18</sup>F]F-sodium fluoride positron emission tomography/computed tomography- red arrows: visible local uptakes out of the valve (aortic annulus calcifications); (<b>E</b>) TAVI valve long axis; (<b>F</b>) TAVI valve short axis.</p>
Full article ">Figure 3
<p>The methodology of leaflet ROI measurement in PET/CT examinations (<b>A</b>)—TAVI Evolut R Valve on CT—image used for estimation of leaflets localization and the choice of ROI levels. The top, middle, bottom cross-section of value used for measurements were marked with colors; Cross-sections of the valve on PET/CT examination (<b>B</b>)—on the top level (blue color); (<b>C</b>)—middle level (red color), yellow and black contour show method of inner and outer outline (ROI) for SUV measurements; (<b>D</b>)—bottom level (green color).</p>
Full article ">Figure 4
<p>(<b>A</b>) Spearman’s correlation coefficient between effective orifice area at 1 month and [<sup>18</sup>F]F-fluorodeoxyglucose (HU) assessed at 6 month; (<b>B</b>) Spearman’s correlation coefficient between effective orifice area at 6 months and [<sup>18</sup>F]F-fluorodeoxyglucose (HU) assessed at 6 month; (<b>C</b>) Spearman’s correlation coefficient between effective orifice area at 1 month and maximal [<sup>18</sup>F]F-fluorodeoxyglucose assessed for bottom segment assessed at 6 months of FU period.</p>
Full article ">Figure 5
<p>(<b>A</b>) Spearman’s correlation coefficient between mean aortic valve gradient measured at baseline and [<sup>18</sup>F]F-fluorodeoxyglucose (HU) measured at 6 months after TAVI procedure. (<b>B</b>) Spearman’s correlation coefficient between maximal aortic valve gradient measured at baseline and [<sup>18</sup>F]F-fluorodeoxyglucose (HU) measured at 6 months after TAVI procedure (<b>C</b>) Spearman’s correlation coefficient between maximal aortic valve gradient measured at 6 months and mean [<sup>18</sup>F]F-sodium fluoride uptake of top segment corrected by mediastinal blood pool structures uptake assessed at 6 months after TAVI procedure.</p>
Full article ">Figure 6
<p>(<b>A</b>) Spearman’s correlation coefficient between valve type and mean [<sup>18</sup>F]F-fluorodeoxyglucose top segment measured at baseline after TAVI procedure. (<b>B</b>) Spearman’s correlation coefficient between valve type and maximal [<sup>18</sup>F]F-FDG top segment measured at baseline after TAVI procedure.</p>
Full article ">
Back to TopTop